查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832142

動物抗菌肽市場（按產品類型、應用和最終用戶）—2025-2032 年全球預測

Animal Antibacterial Peptide Market by Product Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，獸用抗菌肽市場將成長至 146.8 億美元，複合年成長率為 17.40%。

主要市場統計數據
基準年2024年 40.6億美元
預計2025年 47.7億美元
預測年份：2032年 146.8億美元
複合年成長率（%） 17.40%

獸用抗菌肽的策略方向，包括科學進步、監管變化、相關人員獎勵以及商業化的實際採用途徑

隨著相關人員對日益成長的抗生素抗藥性和不斷變化的監管預期做出反應，獸用抗菌肽領域已進入科學和商業性利益日益成長的時期。基於胜肽的抗菌策略利用多種生物機制，具有特異性，可減少抗藥性細菌的產生，並與綜合動物健康計劃相容。胜肽合成、製劑和標靶遞送技術的發展已將許多概念從學術概念驗證推進到轉化開發階段，促使更廣泛的商業相關人員將胜肽評估為傳統抗生素的可行替代品或補充品。因此，獸醫、飼料配方師、水產養殖生產商和生物技術公司正在重新評估其治療通訊協定、牛健康經濟學和產品定位，並更清楚地了解胜肽解決方案獨特的風險回報狀況。

從實驗室創新到商業性化的轉變需要克服科學檢驗、生產複雜性和監管協調等諸多挑戰。強大的分析方法和可擴展的合成平台的引入降低了技術壁壘，而佐劑和遞送技術的進步則提高了體內療效和穩定性。這些趨勢的融合為那些能夠整合多學科能力、與監管機構及早溝通並制定可操作證據生成策略的組織打開了機會之窗。展望未來，成功將取決於能否將機制效益轉化為可證明的動物健康成果、營運相關性以及能夠引起不同最終用戶共鳴的商業性價值提案。

透過合成突破、診斷整合和不斷發展的監管接受度，探索影響獸用抗菌肽發展的關鍵轉變

在技​​術、監管和市場催化劑的推動下，獸用抗菌肽領域正在經歷變革，這些因素正在重新定義競爭動態。在技​​術方面，合成創新和純化製程的改進顯著減少了關鍵的技術瓶頸，使製造商能夠生產出保真度更高、理化性質更精準的胜肽。同時，精準診斷和病原體監測正在推動更有針對性的治療和預防干涉措施，增強了那些具有窄頻譜和物種特異性活性並最大程度減少微生物組破壞的產品的商業性價值。

監管態度也在不斷演變。只要提交嚴格的安全性和有效性數據，監管機構對能夠清楚證明動物福利或環境效益的替代抗菌藥物的接受度日益提高。這種監管勢頭正激勵製造商推行系統性的證據生成項目，並將田間試驗和療效比較終點納入其中。同時，飼料製造商和水產養殖戶等終端用戶正在尋求能夠與現有生產系統無縫整合的解決方案，這催生了對在飼料基質和水中穩定且劑量可預測的配方的需求。這種累積的轉變有利於那些採用系統化方法的組織，該方法能夠協調研發、製造和商業化，從而減少產品屬性與營運現實之間的摩擦。

重點評估2025年美國累積關稅措施將如何影響胜肽原料採購、契約製造決策與供應鏈彈性策略

2025年美國關稅措施加強了參與獸用抗菌肽開發和商業化的機構對供應鏈的考量。由於胜肽生產通常依賴專門的原料、試劑和外包合成能力，關稅政策的變化將影響籌資策略以及全球製造與國內製造的相對競爭力。先前依賴低成本國際供應商的公司正在重新評估總到岸成本、前置作業時間和庫存政策，以降低關稅波動帶來的風險。隨著這些策略調整的實施，一些公司正在探索近岸外包或建立冗餘供應商網路，以保持生產連續性並加快對需求波動的反應。

在營運層面，與關稅相關的成本壓力可能會影響垂直整合、契約製造夥伴關係關係以及分析測試和最終配方等高價值活動選址的決策。擁有靈活供應鏈的公司能夠調整採購、認證替代試劑並調整批次調度，從而更好地應對關稅帶來的干擾，同時又不影響開發和商業化時間表。此外，對採購彈性的日益關注正在推動對供應商資質資格確認、策略性庫存緩衝和合約保障措施的投資，從而降低價格衝擊的風險。總而言之，到2025年，關稅變化的累積影響凸顯了積極主動地重新設計供應鏈、進行情境規劃以及更謹慎地協調製造策略和商業性節奏的必要性。

全面的細分洞察將產品類型、應用和最終用戶組合與證據需求、配方需求和市場途徑選擇聯繫起來

了解細分市場對於設計符合客戶需求和技術可行性的產品系列和商業化路徑至關重要。從產品類型的角度來看，天然胜肽和合成胜肽之間存在著一個關鍵區別，而合成胜肽又根據鍊長進一步細分為長鏈、中鍊和短鏈，這些類別的穩定性、效力和生產影響各不相同。這些產品層面的屬性會影響配方選擇、給藥途徑和成本結構，並指南企業應將製程開發和分析表徵工作的重點放在何處。

不同的使用情況顯示出不同的證據要求和採用曲線。預防性用途，包括疾病預防策略和疫苗佐劑，需要強大的安全性，並在群體免疫或降低疾病發生率方面具有明顯的益處。治療性用途分為感染疾病治療和皮膚病治療，每種用途都需要受控的臨床評估和給藥策略，以應對動物種類、年齡和健康狀況的差異。使用要求和產品特性之間的相互作用將決定臨床試驗的設計、監管途徑的選擇以及可申請的權利要求的性質。

最終用戶細分凸顯了水產養殖場、飼料製造商、研究機構和獸醫診所之間在營運和商業化方面的差異。飼料製造商必須客製化水產飼料和牲畜飼料的兼容性，並強調加工穩定性和劑量均勻性。同時，研究機構（包括學術機構和生物技術公司）推動早期發現、機制闡明和轉化研究。獸醫診所區分大型和小型動物診所的需求，這會影響劑型、給藥途徑和從業人員訓練需求。這些橫斷面細分維度清楚地表明，產品開發和商業化不可能千篇一律。相反，需要根據每個細分領域的技術限制和決策促進因素量身定做證據包、配方策略和上市模式。

美洲、歐洲、中東和非洲以及亞太地區的商業化和監管觀點將推動不同的採用路徑和戰略重點

在獸用抗菌肽領域，監管策略、商業化時機和投資重點因地區而異。在美洲，監管機構和相關人員優先考慮抗菌藥物的管理和顯著減少抗生素依賴，從而創造出動物健康結果和經濟合理性影響採購決策的環境。該地區擁有跨國動物用藥品公司，並建立了成熟的製造外包網路，這使得透過監管和臨床閾值的候選藥物能夠快速擴大規模，但也加劇了爭奪獸醫和生產商注意力的競爭。

歐洲、中東和非洲的法律規範往往不盡相同，歐洲司法管轄區通常對安全性和環境影響設定更高的標準，而該地區其他國家可能優先考慮可及性和可負擔性。在這些地區營運的製造商必須協調不同的核准途徑和預期數據，預測最嚴格的監管要求，同時設計適合當地商業條件的證據產生策略。水產養殖和集約化畜牧生產的快速成長對傳統抗生素的替代品產生了巨大的需求，一些市場的監管現代化為新療法鋪平了道路。然而，亞太地區也強調成本競爭力和供應鏈接接近性，迫使公司優先考慮定價策略和當地製造夥伴關係。任何地區的成功都依賴於將科學檢驗與尊重當地監管細微差別和客戶經濟的務實商業化方法相結合。

競爭和企業創新情報，展示現有企業、生物技術創新者和製造專家如何合作推進胜肽候選物並為商業化做好準備

動物用藥品公司、新興的生物技術公司、專業的肽類研發公司和受託製造組成。現有的動物用藥品公司在監管事務、分銷網路和客戶關係方面擁有優勢，並且能夠在有證據支持其臨床和經濟價值的情況下，將胜肽產品納入其現有產品組合。規模較小的生物技術公司和大學衍生公司經常推動早期創新，推動新的序列、交付平台和作用機制洞察，從而顛覆傳統方法。

策略夥伴關係和授權安排是填補能力差距和加速商業化的常用機制。大型公司可能會與多肽專家達成研究合作或共同開發契約，以獲得專有化學和可擴展的合成方法，而合約開發和生產組織在將候選化合物從實驗室轉移到符合GMP標準的生產過程中發揮關鍵作用。投資者和企業開發團隊越來越關注那些在多肽序列和製劑方面展示清晰的轉化途徑、可重複的生產流程以及可防禦的智慧財產權的公司。競爭優勢通常取決於強力的臨床證據、穩健的生產能力以及提供適合現有動物用藥品工作流程的實用劑型的能力。

向產業領導者提供可行的策略建議，以加速證據產生、確保供應鏈的彈性、儘早與監管機構接觸並設計以最終用戶為中心的商業化策略

產業領導者應實施一系列優先行動，加速負責任的採用，並在管理技術和商業性風險的同時，搶佔先發優勢。這種雙重方法既在理想條件下有效，又在實際運作中體現出實際效益。其次，透過制定模組化製造策略，將關鍵品質屬性的內部能力與提供規模化和冗餘能力的合約合作夥伴結合，從而降低供應風險和與關稅相關的中斷。

第三，在開發早期就制定監管參與計劃，使研究設計與預期的嚴格要求保持一致，並加快跨多個司法管轄區的核准。第四，設計產品形式和分銷模式，透過強調飼料相容配方、易於管理的輸送系統以及對從業人員的清晰指導，最大限度地減少對最終用戶現有工作流程的干擾。第五，尋求將專有胜肽技術與分銷管道和配方專業知識相結合的策略聯盟，以實現更快的市場准入和更廣泛的應用。實施這些建議需要跨職能管治、嚴格的產品組合優先排序，以及試行能夠反映個別最終使用者細微需求的創新商業模式的意願。

透明的調查方法結合了結構化的相關人員訪談、技術文獻綜述、監管分析和跨源檢驗，確保得出可靠且可行的結論

本分析整合了一級和二級研究、技術文獻綜述和相關人員參與，旨在形成基於證據的獸用抗菌肽觀點。一級研究包括對獸醫、飼料配方師、契約製造製造商和研究科學家的結構化訪談，旨在將技術主張轉化為實際操作，並揭示該領域應用面臨的障礙。二級資訊涵蓋同行評審文獻、監管指導文件和專利申請，旨在揭示技術發展軌跡和智慧財產權主題。

此分析方法將訪談資料的定性主題分析與跨司法管轄區法規結構的比較評估相結合，以突出不同市場對證據預期的差異。檢驗是透過跨資料來源的三角測量以及與專家的後續諮詢來實現的，以檢驗假設並完善解釋。此方法強調假設的透明度、對實證結果的保守解釋，以及對既定事實和新興假設的明確區分。結論盡可能反映基於可複製方法和支持性技術文獻的共識觀點，確保建議切實可行並與當前的科學和監管現實一致。

總結結論，整合技術前景、商業現實和策略路徑，以指南獸用抗菌肽的採用和投資決策

綜上所述，獸用抗菌肽是減少對傳統抗生素依賴、改善動物健康和生產永續性的更廣泛策略中一個前景廣闊且實用的組成部分。胜肽設計和遞送方面的科學進步，加上監管機構對替代品的開放態度，正在提升胜肽類干預措施的潛力。然而，成功的商業化取決於安全性和有效性的嚴格證據、生產的擴充性以及適應不同最終用戶的現有營運模式的能力。整合跨職能能力、尋求策略夥伴關係關係並採用有計劃的供應鏈和監管策略的組織可能最有能力將科學潛力轉化為商業性影響力。

展望未來，胜肽的廣泛應用之路可能是一個循序漸進且主導。早期的成功可能集中在肽比其他替代品具有明顯優勢的利基領域，例如局部的預防應用以及局部給藥限制全身暴露的皮膚病治療。經濟高效的生產和可靠的臨床數據的累積可能推動胜肽的更廣泛應用。對於那些在科學嚴謹性和切合實際的商業化計畫之間取得平衡的相關人員來說，胜肽提供了一種可靠的途徑，既能實現管理目標，又能保持生產力和動物福利。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大採用富含抗菌肽衍生物的植物來源飼料補充劑來提高牲畜免疫力
  • 針對家禽生產系統中特定通用感染疾病菌株的人工抗菌肽的開發
  • 胜肽遞送技術的進展，例如用於在反芻動物胃腸道中定向釋放的奈米膠囊技術
  • 北美和歐洲的監管激勵措施正在推動對非抗生素生長促進劑的研究投資，以改善豬隻的健康
  • 新興的噬菌體胜肽混合治療方法可用於對抗養殖魚類抗生素抗藥性感染疾病
  • 生技新創公司與動物用藥品公司建立Start-Ups夥伴關係，加速新型胜肽療法的商業化
  • 整合人工智慧驅動的胜肽設計平台可最佳化抗菌功效並縮短動物保健領域的開發時間

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：動物抗菌胜肽市場（依產品類型）

  • 天然胜肽
  • 合成胜肽
    • 長鏈
    • 中型鏈條
    • 短鏈

第9章動物抗菌肽市場應用

  • 促進生長
  • 預防
    • 疾病預防
    • 疫苗佐劑
  • 治療
    • 感染疾病治療
    • 皮膚病治療

第 10 章動物抗菌肽市場（按最終用戶）

  • 水產養殖場
  • 飼料生產商
    • 水產飼料
    • 牲畜飼料
  • 研究所
    • 學術機構
    • 生技公司
  • 獸醫診所
    • 大型動物治療
    • 小動物治療

第 11 章：動物抗菌胜肽市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章動物抗菌胜肽市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 13 章：各國動物抗菌胜肽市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Esco Aster Pte. Ltd.
    • Biosynth Ltd
    • Vetoquinol SA
    • Phibro Animal Health Corporation
    • Dechra Pharmaceuticals PLC
    • Neogen Corporation
Product Code: MRR-4369010662C8

The Animal Antibacterial Peptide Market is projected to grow by USD 14.68 billion at a CAGR of 17.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.06 billion
Estimated Year [2025] USD 4.77 billion
Forecast Year [2032] USD 14.68 billion
CAGR (%) 17.40%

A strategic orientation to animal antibacterial peptides that frames scientific advances, regulatory shifts, stakeholder incentives, and practical adoption pathways for commercialization

The animal antibacterial peptide space has entered a period of intensified scientific and commercial attention as stakeholders respond to rising antimicrobial resistance and shifting regulatory expectations. Peptide-based antimicrobial strategies draw on diverse biological mechanisms that offer specificity, reduced propensity for resistance selection, and compatibility with integrated animal health programs. Advances in peptide synthesis, formulation, and targeted delivery have moved many concepts from academic proof-of-concept to translational development, prompting a broader set of commercial actors to evaluate peptides as viable alternatives or complements to traditional antibiotics. As a result, veterinarians, feed formulators, aquaculture operators, and biotechnology firms are reassessing therapeutic protocols, herd health economics, and product positioning with a clearer appreciation for the unique risk-return profile of peptide solutions.

Transition from laboratory innovation to commercial readiness requires navigating scientific validation, manufacturing complexity, and regulatory alignment. The introduction of robust analytical methods and scalable synthesis platforms has reduced technical barriers, while simultaneous progress in adjuvant and delivery technologies has enhanced in vivo efficacy and stability. These converging trends create a window of opportunity for organizations that can integrate multidisciplinary capabilities, engage early with regulatory bodies, and design pragmatic evidence-generation strategies. Moving forward, success will hinge on translating mechanistic advantages into demonstrable animal health outcomes, operational compatibility, and commercial value propositions that resonate across diverse end users.

An in-depth exploration of the pivotal shifts reshaping animal antibacterial peptide development driven by synthesis breakthroughs, diagnostics integration, and evolving regulatory acceptance

The landscape for animal antibacterial peptides is undergoing transformative shifts driven by technological, regulatory, and market catalysts that are redefining competitive dynamics. On the technological front, synthesis innovations and improved purification processes have materially reduced key technical bottlenecks, enabling manufacturers to produce peptides with higher fidelity and tailored physicochemical properties. Concurrently, precision diagnostics and pathogen surveillance are enabling more targeted therapeutic and prophylactic interventions, which strengthens the commercial case for products that offer narrow-spectrum or species-specific activity and minimize microbiome disruption.

Regulatory attitudes are also evolving: authorities are increasingly receptive to antimicrobial alternatives that demonstrate clear animal welfare benefits and environmental advantages, provided that rigorous safety and efficacy data accompany submissions. This regulatory momentum incentivizes manufacturers to pursue structured evidence-generation programs that incorporate field trials and comparative effectiveness endpoints. In parallel, end users such as feed manufacturers and aquaculture producers are seeking solutions that integrate seamlessly with existing production systems, creating demand for formulations that are stable in feed matrices or water and deliver predictable dosing. These cumulative shifts favor organizations that adopt a systems-based approach, aligning R&D, manufacturing, and commercialization to reduce friction between product attributes and operational realities.

A focused assessment of how cumulative United States tariff measures enacted in 2025 influence peptide input sourcing, contract manufacturing decisions, and supply chain resilience strategies

United States tariff actions in 2025 have amplified supply chain considerations for organizations involved in animal antibacterial peptide development and commercialization. Because peptide production often depends on specialized raw materials, reagents, and outsourced synthesis capacity, changes in tariff policy influence procurement strategies and the relative competitiveness of global versus domestic manufacturing. Firms that previously relied on low-cost international suppliers are reassessing total landed cost, lead times, and inventory policies to mitigate exposure to tariff volatility. As these strategic adjustments occur, some organizations are exploring nearshoring or establishing redundant supplier networks to preserve continuity of production and accelerate response to demand fluctuations.

At the operational level, tariff-related cost pressures can affect decisions about vertical integration, contract manufacturing partnerships, and the location of high-value activities such as analytical testing and final formulation. Companies with flexible supply chains that can adapt sourcing, qualify alternate reagents, and adjust batch scheduling will be better positioned to absorb tariff-driven dislocations without compromising timelines for development and commercialization. Additionally, heightened attention to procurement resilience is catalyzing investments in supplier qualification, strategic inventory buffering, and contractual safeguards that reduce the risk of price shocks. Taken together, the cumulative implications of tariff shifts in 2025 underscore the need for proactive supply chain redesign, scenario planning, and a more deliberate alignment of commercial cadence with manufacturing strategy.

Comprehensive segmentation-driven insight linking product type distinctions, application pathways, and end user configurations to evidence needs, formulation imperatives, and route-to-market choices

Understanding segmentation is essential to designing product portfolios and commercialization pathways that align with customer needs and technical feasibility. When products are viewed through the lens of product type, a primary distinction emerges between naturally derived peptides and synthetic peptides, with synthetic variants further differentiated by chain length into long chain, medium chain, and short chain classes that carry distinct stability, potency, and manufacturing implications. These product-level attributes influence formulation choices, route of administration, and cost structures, and they guide where firms should focus process development and analytical characterization efforts.

Viewing the landscape by application reveals divergent evidence requirements and adoption curves. Growth promotion approaches prioritize compatibility with feed systems and predictable performance under production conditions, whereas prophylactic uses, which include disease prevention strategies and vaccination adjuvants, demand strong safety profiles and clear benefits to herd immunity or disease incidence reduction. Therapeutic applications break down into infection treatment and skin disease treatment, each needing controlled clinical evaluation and dosing strategies that accommodate variability in species, age, and health status. The interplay between application demands and product attributes determines clinical trial design, regulatory pathway selection, and the nature of claims that can be pursued.

End user segmentation highlights operational and commercialization differences across aquaculture farms, feed manufacturers, research institutes, and veterinary clinics. Feed manufacturers must reconcile compatibility with aquafeed and livestock feed formats, focusing on processing stability and uniformity of dosing, while research institutes-which span academic institutes and biotech companies-drive early-stage discovery, mechanism elucidation, and translational studies. Veterinary clinics differentiate between large animal practice and small animal practice needs, which affects dosage forms, administration routes, and practitioner training requirements. These cross-cutting segmentation dimensions underscore that product development and commercialization cannot be one-size-fits-all; instead, they require tailored evidence packages, formulation strategies, and go-to-market models calibrated to each segment's technical constraints and decision drivers.

Regional commercialization and regulatory perspectives across the Americas, Europe Middle East and Africa, and Asia-Pacific that frame differential adoption paths and strategic priorities

Regional dynamics materially shape regulatory strategy, commercialization timing, and investment priorities across the animal antibacterial peptide domain. In the Americas, regulatory bodies and industry stakeholders emphasize antimicrobial stewardship and measurable reductions in antibiotic reliance, creating an environment where demonstrable animal health outcomes and economic justification influence purchasing decisions. This region's strong presence of multinational animal health companies and established contract manufacturing networks supports rapid scale-up for candidates that clear regulatory and clinical thresholds, but it also intensifies competition for veterinarian and producer attention.

In Europe, the Middle East and Africa, regulatory frameworks tend to be heterogeneous, with European jurisdictions often setting higher bars for safety and environmental impact while other countries within the broader region may prioritize access and affordability. Manufacturers seeking to operate across these territories must reconcile disparate approval pathways and data expectations, designing evidence generation strategies that anticipate the most rigorous regulatory requirements while remaining adaptable to local commercial conditions. The Asia-Pacific region presents a different set of dynamics: rapid growth in aquaculture and intensive livestock production creates significant demand for alternatives to conventional antibiotics, and regulatory modernization in several markets is opening pathways for novel interventions. However, the Asia-Pacific landscape also emphasizes cost competitiveness and supply chain proximity, so organizations must weigh pricing strategies and local manufacturing partnerships to gain traction. Across all regions, success depends on aligning scientific validation with pragmatic commercialization approaches that respect local regulatory nuance and customer economics.

Competitive and corporate innovation intelligence showing how incumbents, biotech innovators, and manufacturing specialists collaborate to advance peptide candidates and commercial readiness

The competitive environment for animal antibacterial peptides is characterized by a mix of established animal health companies, emerging biotech players, specialized peptide developers, and contract manufacturing organizations that together create a complex innovation ecosystem. Incumbent animal health firms bring strengths in regulatory navigation, distribution networks, and customer relationships, enabling them to integrate peptide-based products into existing portfolios where evidence supports clinical and economic value. Conversely, smaller biotechnology companies and academic spinouts frequently drive early-stage innovation, advancing novel sequences, delivery platforms, and mechanism-of-action insights that disrupt conventional approaches.

Strategic partnerships and licensing arrangements are common mechanisms to bridge capability gaps and accelerate commercialization. Larger companies may form research collaborations or co-development agreements with peptide specialists to access proprietary chemistries and scalable synthesis methods, while contract development and manufacturing organizations play a pivotal role in moving candidates from bench to GMP-compliant production. Investors and corporate development teams are increasingly attentive to companies that demonstrate clear translational pathways, reproducible manufacturing processes, and defensible intellectual property around peptide sequences and formulations. Competitive differentiation frequently rests on a combination of strong clinical evidence, manufacturing robustness, and the ability to deliver practical administration formats that fit into existing animal health workflows.

Actionable strategic recommendations for industry leaders to accelerate evidence generation, secure resilient supply chains, engage regulators early, and design end user-centric commercialization strategies

Industry leaders should execute a set of prioritized actions to accelerate responsible adoption and capture first-mover advantages while managing technical and commercial risk. First, invest in rigorous, outcome-focused evidence generation that pairs controlled clinical studies with real-world production trials; this dual approach demonstrates both efficacy under ideal conditions and practical benefits under operational realities. Second, develop modular manufacturing strategies that combine in-house capabilities for critical quality attributes with qualified contract partners to provide scale and redundancy, thereby mitigating supply risk and tariff-related disruptions.

Third, build regulatory engagement plans early in development to align study designs with the most stringent expected requirements and to accelerate approvals across multiple jurisdictions. Fourth, design product formats and distribution models that minimize disruption to end users' existing workflows by emphasizing feed-compatible formulations, easy-to-administer dosing systems, and clear guidance for practitioners. Fifth, pursue strategic alliances that couple proprietary peptide technologies with distribution channels and formulation expertise, enabling faster market entry and broader adoption. Implementing these recommendations requires cross-functional governance, disciplined portfolio prioritization, and a willingness to pilot innovative commercial models that reflect the nuanced needs of different end users.

Transparent research methodology combining structured stakeholder interviews, technical literature review, regulatory analysis, and cross-source validation to ensure robust and actionable conclusions

This analysis synthesizes primary and secondary research, technical literature review, and stakeholder engagement to construct an evidence-based perspective on animal antibacterial peptides. Primary inputs included structured interviews with veterinarians, feed formulators, contract manufacturers, and research scientists to ground technical claims in operational realities and to identify adoption barriers encountered in field settings. Secondary inputs encompassed peer-reviewed literature, regulatory guidance documents, and patent filings to map technological trajectories and intellectual property themes, while careful screening avoided relying on single-source commercial summaries.

Analytical methods combined qualitative thematic analysis of interview data with comparative evaluation of regulatory frameworks across jurisdictions to highlight cross-market differences in evidence expectations. Validation occurred through triangulation across data sources and follow-up consultations with subject-matter experts to test assumptions and refine interpretations. The approach emphasized transparency in assumptions, conservative interpretation of experimental results, and clear delineation between established facts and emerging hypotheses. Wherever possible, conclusions reflect consensus views rooted in reproducible methods and corroborating technical literature, ensuring that recommendations are actionable and aligned with current scientific and regulatory realities.

Concluding synthesis that integrates technical promise, commercialization realities, and strategic pathways to guide adoption and investment decisions in animal antibacterial peptides

In conclusion, animal antibacterial peptides represent a promising and pragmatic element of a broader strategy to reduce reliance on traditional antibiotics while improving animal health outcomes and production sustainability. Scientific advances in peptide design and delivery, coupled with evolving regulatory openness to alternatives, have improved the viability of peptide-based interventions. Nonetheless, successful commercialization depends on rigorous evidence of safety and efficacy, manufacturing scalability, and the ability to fit into existing operational models across diverse end users. Organizations that integrate cross-functional capabilities, pursue strategic partnerships, and adopt deliberate supply chain and regulatory strategies will be best positioned to translate scientific potential into commercial impact.

Looking ahead, the path to widespread adoption will be incremental and evidence-driven. Early successes will likely focus on niches where peptides clearly outperform alternatives, such as targeted prophylactic applications or skin disease treatments where topical or localized delivery reduces systemic exposure. Broader adoption will follow as cost-effective manufacturing and robust clinical datasets accumulate. For stakeholders that balance scientific rigor with pragmatic commercialization planning, peptides offer a credible route to meeting stewardship goals while preserving productivity and animal welfare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased adoption of plant-based feed supplements enriched with antibacterial peptide derivatives to improve livestock immunity
  • 5.2. Development of engineered antimicrobial peptides targeting specific zoonotic bacteria strains in poultry production systems
  • 5.3. Advances in peptide delivery technologies such as nanoencapsulation for targeted release in ruminant gastrointestinal tracts
  • 5.4. Regulatory incentives in North America and Europe driving research investments in non-antibiotic growth promotors for swine health
  • 5.5. Emergence of bacteriophage-peptide hybrid treatments for combating antibiotic-resistant infections in aquaculture species
  • 5.6. Strategic collaborations between biotech startups and veterinary pharmaceutical companies accelerating novel peptide therapeutics commercialization
  • 5.7. Integration of AI-driven peptide design platforms to optimize antibacterial efficacy and reduce development timelines in animal health

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Antibacterial Peptide Market, by Product Type

  • 8.1. Naturally Derived Peptide
  • 8.2. Synthetic Peptide
    • 8.2.1. Long Chain
    • 8.2.2. Medium Chain
    • 8.2.3. Short Chain

9. Animal Antibacterial Peptide Market, by Application

  • 9.1. Growth Promotion
  • 9.2. Prophylactic
    • 9.2.1. Disease Prevention
    • 9.2.2. Vaccination Adjuvant
  • 9.3. Therapeutic
    • 9.3.1. Infection Treatment
    • 9.3.2. Skin Disease Treatment

10. Animal Antibacterial Peptide Market, by End User

  • 10.1. Aquaculture Farms
  • 10.2. Feed Manufacturers
    • 10.2.1. Aquafeed
    • 10.2.2. Livestock Feed
  • 10.3. Research Institutes
    • 10.3.1. Academic Institute
    • 10.3.2. Biotech Company
  • 10.4. Veterinary Clinics
    • 10.4.1. Large Animal Practice
    • 10.4.2. Small Animal Practice

11. Animal Antibacterial Peptide Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Animal Antibacterial Peptide Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Animal Antibacterial Peptide Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Zoetis Inc.
    • 14.3.2. Elanco Animal Health Incorporated
    • 14.3.3. Merck & Co., Inc.
    • 14.3.4. Boehringer Ingelheim International GmbH
    • 14.3.5. Esco Aster Pte. Ltd.
    • 14.3.6. Biosynth Ltd
    • 14.3.7. Vetoquinol S.A.
    • 14.3.8. Phibro Animal Health Corporation
    • 14.3.9. Dechra Pharmaceuticals PLC
    • 14.3.10. Neogen Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. ANIMAL ANTIBACTERIAL PEPTIDE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. ANIMAL ANTIBACTERIAL PEPTIDE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL ANTIBACTERIAL PEPTIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLIN